AN2 Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical firm specializing in treatments for severe infectious diseases, announced participation in two investor conferences in November 2022. The Stifel 2022 Healthcare Conference will take place from November 15-17 in New York, where CEO Eric Easom will present on November 16 at 9:10 a.m. ET. Additionally, Easom will join a fireside chat at the 5th Annual Evercore ISI HealthConX Conference on November 30 at 2:15 p.m. ET. Webcasts for both events will be accessible on the company’s website.

MENLO PARK, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November.

Details of the events are as follows:

Stifel 2022 Healthcare Conference, November 15-17, 2022, New York, New York.

• Eric Easom, Co-Founder, President and CEO will present a corporate overview on Wednesday, November 16 at 9:10 a.m. ET.
  

5^th Annual Evercore ISI HealthConX Conference (virtual).

• Eric Easom, Co-Founder, President and CEO will participate in a fireside chat on Wednesday, November 30 at 2:15 p.m ET.
  

Webcasts can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation and fireside chat.

About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our lead candidate is epetraborole, which we are studying in a pivotal Phase 2/3 trial as a once-daily, oral treatment with a novel mechanism of action for patients with NTM lung disease, a rare, chronic, and progressive infectious disease caused by bacteria, known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT: 
Anne Bowdidge 
ir@an2therapeutics.com 

FAQ

What are the details of AN2 Therapeutics' participation in upcoming conferences in November 2022?

AN2 Therapeutics will participate in the Stifel 2022 Healthcare Conference from November 15-17, where CEO Eric Easom presents on November 16 at 9:10 a.m. ET. They will also participate in the 5th Annual Evercore ISI HealthConX Conference on November 30 at 2:15 p.m. ET.

How can I access the webcasts for AN2 Therapeutics' conference presentations?

Webcasts for both the Stifel Conference and the Evercore ISI HealthConX Conference can be accessed via the Investors section on AN2 Therapeutics' website, with archived replays available for at least 30 days.

Who is presenting for AN2 Therapeutics at the investor conferences in November 2022?

Eric Easom, Co-Founder, President and CEO of AN2 Therapeutics, will present at both the Stifel 2022 Healthcare Conference and the Evercore ISI HealthConX Conference.

What is the focus of AN2 Therapeutics as a company?

AN2 Therapeutics is focused on developing treatments for rare, chronic, and serious infectious diseases, with a particular emphasis on addressing high unmet needs.

What is the lead candidate being developed by AN2 Therapeutics?

AN2 Therapeutics' lead candidate is epetraborole, which is currently being studied as a once-daily oral treatment for NTM lung disease.